Clinical Trial Update: Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) [Phase 2]

View source ↗

Summary

Phase II trial update for SCH66336 (a farnesyltransferase inhibitor) in chronic myelogenous leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCH66336 (SCH66336)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelogenous Leukemia, Chronic | Phase 2 | Status: COMPLETED